How many injections of Ozempic for weight loss — and what the evidence actually says

What the STEP 1 trial tells us about semaglutide injections for weight loss

The landmark evidence here isn't from Ozempic's diabetes trials. It comes from the STEP 1 trial, published in the New England Journal of Medicine, which tested weekly semaglutide 2.4mg injections in adults with obesity but without diabetes over 68 weeks. Participants followed a gradual escalation, starting at 0.25mg once weekly, then stepping up through 0.5mg, 1.0mg and 1.7mg, spending roughly four weeks at each level before reaching the 2.4mg maintenance dose. Average weight reduction at 68 weeks was around 15% of body weight. That is a meaningful figure, but it only applied to the specific dose and schedule the trial tested. The 1mg Ozempic dose used in diabetes management was never the dose under study. Prescribers treating weight loss with semaglutide work from this evidence base, which is why the injection schedule for weight management looks the way it does. The number of injections isn't arbitrary, it reflects the titration the data supports.

For a fuller picture of how semaglutide works on appetite and weight, the mechanism is the same whether the brand name on the pen is Ozempic or Wegovy, but the licensed dose, the indication, and the clinical context are different.

Why Ozempic isn't the answer even if the drug is the same

A question worth addressing directly: if Ozempic and Wegovy both contain semaglutide, why does the brand name change anything? The short answer is that the UK licence does. The NHS confirms that Ozempic is licensed for type 2 diabetes, not weight management, and that prescribing it off-label for weight loss falls outside authorised use. Wegovy was specifically developed and trialled at the higher 2.4mg weekly dose, submitted for regulatory review on that basis, and granted a distinct marketing authorisation by the MHRA. The injection pen, the dose increments, and the approved patient population are all different. If you want to understand how weight loss injections like Ozempic compare to licensed alternatives, the distinctions in indication, dose, and regulatory status are the right place to start. Using Ozempic for weight loss without a prescription (or obtaining it from an unverified seller) sits outside clinical supervision and carries real risks, including counterfeit products that have caused harm. The MHRA has seized large quantities of fake weight-loss pens and continues to warn the public about sellers operating without a valid prescription process. There is no shortcut here that is also safe.

If you're weighing up your options on cost, our overview of licensed weight-loss treatments lays out what's available and what to expect from each route.

What the licensed injection schedule actually looks like in practice

For Wegovy, the standard titration runs once-weekly injections at 0.25mg for the first month, 0.5mg for the second, 1.0mg for the third, 1.7mg for the fourth, and 2.4mg from the fifth month onward as the maintenance dose. That's a minimum of five months of weekly injections to reach the maintenance level the trials validated. In April 2026 the MHRA approved a single-dose 7.2mg Wegovy pen, extending the maximum licensed dose further for eligible adults, the titration to get there still starts at 0.25mg and works through each step. A quick check you can do right now: count where you'd be in that schedule after three months and you'll immediately see why skipping steps, or starting at a higher dose to save time, isn't how the evidence was built. Your prescriber sets your dose based on how your body is responding, not on a fixed timetable. Injection frequency stays weekly throughout. Injection sites (abdomen, thigh or upper arm) should be rotated each week; guidance on choosing and rotating injection sites is worth reading before you start.

What's licensed for weight loss in the UK, and how to access it

Two injectable medicines hold MHRA licences for weight management in adults in the UK: Wegovy (semaglutide) and Mounjaro (tirzepatide). Neither is Ozempic. Mounjaro works on two gut-hormone receptors rather than one and produced average weight reductions of around 20% at its highest dose in the SURMOUNT-1 trial, a different medicine with a different mechanism and its own injection schedule. Both require a prescription following clinical assessment. How and where to access Wegovy in the UK is a question that comes up often; the route is a regulated online pharmacy or a GP practice where the medicine has been commissioned. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally before any treatment is approved. That's not a slower process, orders placed before noon on a working day are dispatched the same day once approved, with free next-working-day tracked delivery. If you'd like to understand which licensed treatment fits your circumstances, speaking to our prescribers is the right first step.